Drugs / PF-06648671
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02883114 | Sep → Nov 2016 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02407353 | Oct 2015 → Mar 2016 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02440100 | May 2015 → Oct 2016 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02316756 | Dec 2014 → Mar 2015 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06648671 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02440100 ↗ |
| Action | Inhibit | “γ-Secretase modulators (GSMs) represent a promising therapy for Alzheimer's disease by reducing pathogenic amyloid-β (Aβ) peptide production.” PMID 31314925 ↗ Sep 2019 |
| Modality | Small molecule | — CHEMBL3951810 ↗ |
| Route | Oral | “Experimental Pfizer compound which will be dosed as oral suspension” NCT02316756 ↗ |